Why the study?
Data on catheter ablation for VT in HCM remain limited, with prior studies mainly addressing feasibility and safety rather than long-term efficacy or arrhythmogenic substrate characteristics.
Does catheter ablation provide long-term arrhythmia control in patients with hypertrophic cardiomyopathy and sustained ventricular tachycardia?
Population
16 patients with HCM undergoing catheter ablation for sustained VT
Comparison
Combined endocardial/epicardial ablation vs endocardial-only ablation
Design
Retrospective single-center study
Follow-up
Mean 49.6 ± 32.9 months (median 53.4, IQR 18.3–84.6)
Key result
Catheter ablation for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy resulted in a 43.8% VT recurrence rate and a median VT-free survival of 73.5 months.
Authors
Loading...
May support durable VT control in select cases; hypothesis-generating and should not yet change practice.
Observational (n=16)
No
Does catheter ablation provide long-term arrhythmia control in patients with hypertrophic cardiomyopathy and sustained ventricular tachycardia?
Catheter ablation for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy is feasible, safe, and provides acceptable long-term arrhythmia control with a median VT-free survival of 73.5 months.
Keresteci et al. (2026) conducted an observational in Hypertrophic cardiomyopathy with sustained ventricular tachycardia (n=16). Catheter ablation was evaluated on Ventricular tachycardia recurrence. Catheter ablation for sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy resulted in a 43.8% VT recurrence rate and a median VT-free survival of 73.5 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: